- Page 1/8
(A Top Pick May 28/17, Up 22%) It has fully recovered from the Cambridge Analytica furor. He still considers it attractive. Revenue growth is protected to go up along with earnings growth. Earnings per share is 6% higher going forward. It is more attractive than 3 months ago.
(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.
(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.
(A Top Pick May 28/17, Down 7%) It has a 7-8% dividend yield and is being bought out by the parent. He will continue to hold on thinking there is still more upside.
(A Top Pick May 28/17, Down 7%) It has a 7-8% dividend yield and is being bought out by the parent. He will continue to hold on thinking there is still more upside.
He advertized for a news letter he puts out on FB-Q. The experience made him even more bullish on the company. (Analysts’ target: $221.79).
He advertized for a news letter he puts out on FB-Q. The experience made him even more bullish on the company. (Analysts’ target: $221.79).
It is a second chance if you missed out on AMZN-Q. It is the largest E-seller in the world. You get growth and profitability combined. (Analysts’ target: $234.96).
It is a second chance if you missed out on AMZN-Q. It is the largest E-seller in the world. You get growth and profitability combined. (Analysts’ target: $234.96).
It has superior results to Canadian peers. The accident rate has not been lowering because of backup cameras. Profits will improve and the stock will go up. (Analysts’ target: $107.77).
It has superior results to Canadian peers. The accident rate has not been lowering because of backup cameras. Profits will improve and the stock will go up. (Analysts’ target: $107.77).
He would probably wait right now. It has moved up in recent months. The PE is too high. Can they sustain the 20+ revenue rate growth? It has accelerated.
He would probably wait right now. It has moved up in recent months. The PE is too high. Can they sustain the 20+ revenue rate growth? It has accelerated.
(A Top Pick May 28/17, Up 22%) It has fully recovered from the Cambridge Analytica furor. He still considers it attractive. Revenue growth is protected to go up along with earnings growth. Earnings per share is 6% higher going forward. It is more attractive than 3 months ago.